Φορτώνει......
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
ESSENTIALS: Treatment complications in hemophilia A: inhibitors development. Type of FVIII products: the latest updates on plasma‐derived or recombinant FVIII immunogenicity. SIPPET study, the first randomized study contrasting plasma‐derived FVIII and recombinant FVIII products. The impact of other...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Res Pract Thromb Haemost |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055565/ https://ncbi.nlm.nih.gov/pubmed/30046724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12094 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|